While the conformity assessment process is essential for ensuring product safety and compliance, there are several challenges and areas for improvement.
Some EU member states may impose additional national requirements, leading to inconsistencies in the application of the FPR. There is a need for greater alignment and consistency to ensure that products meeting EU standards are accepted across all member states.
The current regulatory framework may not fully encompass emerging biostimulant technologies. EBIC recommends expanding the list of approved components and adopting a criteria-based approach to facilitate the inclusion of new and innovative products.
The conformity assessment process can be complex and administratively burdensome. Streamlining procedures and reducing unnecessary requirements can help make the process more efficient and accessible for manufacturers.